No Data
No Data
More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the
Express News | Chardan Capital Maintains Buy on Adverum Biotechnologies, Adjusts Price Target To $40 ((Reverse Stock Split 1:10))
Adverum Biotechnologies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/18/2024 322.83% Chardan Capital $4 → $40 Maintains Buy 06/25/2024 164.27% Oppenheimer → $25 Initiates
Chardan Research Adjusts Adverum Biotechnologies' PT to $40 From $4, Maintains Buy Rating
Adverum Biotechnologies (ADVM) has an average rating of buy and price targets ranging from $15 to $60, according to analysts by Capital IQ.Price: 8.10, Change: -0.68, Percent Change: -7.74
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $23
Truist Financial analyst Joon Lee maintains $Adverum Biotechnologies(ADVM.US)$ with a buy rating, and sets the target price at $23.According to TipRanks data, the analyst has a success rate of 52.8%
Adverum Biotechnologies' Promising AMD Treatment Advances
No Data